Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) CEO Acquires $1,012,800.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. acquired 60,000 shares of Zenas BioPharma stock in a transaction dated Monday, May 18th. The shares were bought at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the transaction, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. The trade was a 162.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Zenas BioPharma Trading Up 9.6%

Shares of ZBIO opened at $19.56 on Thursday. The company’s fifty day moving average is $20.76 and its 200 day moving average is $26.48. Zenas BioPharma, Inc. has a fifty-two week low of $8.91 and a fifty-two week high of $44.60. The stock has a market capitalization of $1.23 billion, a PE ratio of -2.31 and a beta of -0.61. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. Sell-side analysts expect that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Guggenheim boosted their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research report on Thursday, May 14th. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Morgan Stanley boosted their price target on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.29.

Institutional Trading of Zenas BioPharma

Large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Zenas BioPharma during the fourth quarter valued at $38,000. Quarry LP boosted its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Zenas BioPharma during the third quarter valued at $30,000. CWM LLC boosted its stake in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zenas BioPharma during the fourth quarter valued at $95,000.

Trending Headlines about Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Zenas BioPharma announced that results from the Phase 3 INDIGO registrational trial of obexelimab in IgG4-related disease will be presented at the EULAR 2026 Congress on June 4. A high-profile presentation of late-stage data can raise expectations for the program and act as a stock catalyst. Article Title
• Positive Sentiment: CEO Leon O. Moulder, Jr. bought 60,000 shares at $16.88, a purchase worth about $1.0 million. Insider buying is often viewed as a sign of management confidence in the company’s outlook. Article Title
• Neutral Sentiment: HC Wainwright kept a Buy rating and $44 price target, but cut earnings estimates across several years, including Q2, Q3, Q4 2026 and longer-term forecasts. The lower EPS projections are a mild headwind, but the intact bullish rating suggests the firm still sees upside potential. Article Title

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.